Carnitine consumption and effect of oral supplementation in human pulmonary arterial hypertension: A pilot study

15 August 2024

Evan L. Brittain, Alisha Lindsey, Kelly Burke, Vineet Agrawal, Ivan Robbins, Meredith Pugh, M. Wade Calcutt, Ravi Mallugari, James West, Hui Nian, Anna R. Hemnes

https://doi.org/10.1002/pul2.12425

Abstract

Carnitine is required to transport fatty acid across the mitochondrial membrane to undergo beta oxidation. In addition to disorders of fatty acid metabolism, a relative carnitine deficiency has been reported in pulmonary arterial hypertension (PAH). Here we performed an observational study in which food and supplement consumption were collected in an observation period followed by open label administration of a carnitine supplement to determine feasibility of increasing plasma carnitine levels in humans PAH. We confirmed that relative carnitine deficiency in PAH is not due to reduced dietary consumption and that plasma levels of carnitine can be increased in PAH patients with supplementation that is well tolerated.

Read the full research letter

Share:
Additional comments are available to members. Login or register to become a member today